Phase II Trial of Venetoclax and HMA in FLT3 Mutated AML Patients
A phase II trial is comparing azacitidine and venetoclax to a combination of azacitidine, venetoclax, and gilteritinib in older patients with FLT3 mutated AML.
Asset / Drug
Drug and asset intelligence for azacitidine with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.